L3VLUP
ProSign in

RLMD in the 13F filings

Relmada Therapeutics Inc · CUSIP 75955J402

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q1 2024Q4 2023Q3 2022Q2 2022Q1 2022Q4 2021Q4 2020Q3 2020Q2 2020
Quarter end
30 Sep 2022
the date the book describes
Filed
14 Nov 2022
latest of these filings; the earliest 14 Nov 2022
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2022 and Q3 2022; 1 listed it in both
Shares listed
987,690
combined, among listed positions
Reported value
$37m
combined, at the quarter end

Managers listing RLMD in Q3 2022

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2022, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Point72 Asset Management LP837,190$31m0.12%Trimmed-435,38414 Nov 2022 (the filing on sec.gov)
Schonfeld Strategic Advisors LLC150,500$5.6munder 0.1%Newnew14 Nov 2022 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2022 to Q3 2022, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q1 2022 to 1 in Q2 2026

Tracked managers listing it, at least.

01122Q4 2019Q2 2020Q4 2020Q1 2022Q3 2022Q1 2024Q1 2026Q2 2026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
RLMD by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20191$5.3mn.a.n.a.
Q1 20201$964kn.a.n.a.
Q2 20201$7.4mn.a.n.a.
Q3 20201$7.5mn.a.n.a.
Q4 20201$9.1mn.a.n.a.
Q4 20211$21mn.a.n.a.
Q1 20222$39mn.a.n.a.
Q2 20222$26mn.a.n.a.
Q3 20222$37mn.a.n.a.
Q4 20231$4.9m10
Q1 20241$5.5m01
Q4 20251$35m151
Q1 20261$77m117
Q2 20261$77m1013

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

RLMD and LLY →RLMD and JNJ →RLMD and VRTX →Choose a stock to compare with RLMD →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own RLMD, latest filings →Back to the 13F Explorer →